Literature DB >> 15966964

Health co-morbidities in ageing persons with Down syndrome and Alzheimer's dementia.

M McCarron1, M Gill, P McCallion, C Begley.   

Abstract

BACKGROUND: Consideration of the relationship between physical and mental health co-morbidities in ageing persons with Down syndrome (DS) and Alzheimer's dementia (AD) is of clinical importance both from a care and resource perspective. AIM To investigate and measure health co-morbidities in ageing persons with Down syndrome with and without AD.
METHODS: Recorded physical and mental health needs were ascertained for 124 persons with DS>35 years through a systematic and detailed search of individual medical and nursing case records. Differences in persons with and without AD were investigated, by stage of dementia and by level of intellectual disability (ID). A summed score for health co-morbidities was created and compared using t-tests.
RESULTS: Persons with AD had significantly higher co-morbidity scores than persons without AD (t=-8.992, d.f.=121, P<0.0001). There was also a significant difference in summed co-morbidity scores for persons at end-stage vs. persons at mid-stage AD (t=-6.429, d.f.=56, P<0.0001). No differences were found by level of ID.
CONCLUSIONS: Increasing health co-morbidities in persons with DS and AD have important implications for care and resources. Appropriate environmental supports combined with competent skilled staff are crucial and will have an important impact on the quality of life for this increasingly at risk population.

Entities:  

Mesh:

Year:  2005        PMID: 15966964     DOI: 10.1111/j.1365-2788.2005.00704.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  15 in total

1.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

Review 2.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

3.  Outcome Measures for Clinical Trials in Down Syndrome.

Authors:  Anna J Esbensen; Stephen R Hooper; Deborah Fidler; Sigan L Hartley; Jamie Edgin; Xavier Liogier d'Ardhuy; George Capone; Frances A Conners; Carolyn B Mervis; Leonard Abbeduto; Michael Rafii; Sharon J Krinsky-McHale; Tiina Urv
Journal:  Am J Intellect Dev Disabil       Date:  2017-05

4.  Considerations for measuring individual outcomes across contexts in Down syndrome: Implications for research and clinical trials.

Authors:  Anna J Esbensen; Emily K Schworer; Deborah J Fidler; Angela John Thurman
Journal:  Int Rev Res Dev Disabil       Date:  2022-08-19

5.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

6.  Association between epilepsy and psychiatric disorders in adults with intellectual disabilities: systematic review and meta-analysis.

Authors:  Basma Akrout Brizard; Bharati Limbu; Carolina Baeza-Velasco; Shoumitro Deb
Journal:  BJPsych Open       Date:  2021-05-03

7.  Prevalence of Depression and Dementia among Adults with Developmental Disabilities in Manitoba, Canada.

Authors:  Shahin Shooshtari; Patricia Joan Martens; Charles A Burchill; Natalia Dik; Saba Naghipur
Journal:  Int J Family Med       Date:  2011-08-08

8.  Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway.

Authors:  Fred Andersen; Matti Viitanen; Dag S Halvorsen; Bjørn Straume; Torgeir A Engstad
Journal:  BMC Geriatr       Date:  2011-10-04       Impact factor: 3.921

9.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

10.  Opportunities, barriers, and recommendations in down syndrome research.

Authors:  James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi
Journal:  Transl Sci Rare Dis       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.